- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05229471
Management of Recurrent Venous Thromboembolism During Anticoagulant Treatment in Cancer Patients - a Prospective Cohort Study (REDUCE)
Objective: To prospectively evaluate clinical outcomes during guideline-recommended LMWH dose escalation for recurrent VTE during LMWH or DOAC treatment for cancer-associated thrombosis.
Study design: International, prospective, observational cohort study Study population: Adult cancer patients with symptomatic or incidental recurrent VTE while receiving LMWH or DOACs for acute VTE are eligible. Main exclusion criteria include anticoagulant treatment for the recurrent VTE for more than 72 hours, severe hepatic dysfunction, active bleeding, recent major surgery, uncontrolled hypertension, known bleeding diathesis, and a life expectancy of less than 1 month.
Study procedures: Patients will be managed at the discretion of the treating physician, who will be encouraged to follow guideline recommendations. These guidelines suggest supra-therapeutic dose LMWH for 4 weeks (+/- 5 days) followed by therapeutic dose LMWH or therapeutic dose DOAC, while it is suggested to treat patients with VTE recurrence during maintenance dose LMWH (i.e. 75 to 80% of full therapeutic weight adjusted dose) with therapeutic dose of LMWH or DOAC.
Main study parameters/endpoints: The co-primary outcomes are new symptomatic or incidental recurrent VTE during 3 months of follow-up and on-treatment major bleeding. Secondary outcomes include recurrent incidental VTE, recurrent symptomatic VTE, recurrent incidental or symptomatic proximal or distal DVT, recurrent incidental or symptomatic PE, clinically relevant non-major bleeding, all-cause mortality, and cancer-related mortality. VTE occurring at other sites such as cerebral DVT or splanchnic DVT will also be recorded.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Floris Bosch, Drs.
- Phone Number: 0031 20 5668791
- Email: f.t.bosch@amsterdamumc.nl
Study Contact Backup
- Name: Marcello Di Nisio, Dr.
- Email: mdinisio@unich.it
Study Locations
-
-
-
Chieti, Italy
- Recruiting
- Gabriele D'Annunzio University
-
Contact:
- Marcello Di Nisio
-
-
-
-
-
Amersfoort, Netherlands
- Recruiting
- Meander Medisch Centrum
-
Contact:
- Hans-Martin Otten
-
Amsterdam, Netherlands
- Recruiting
- Amsterdam UMC, location AMC
-
Contact:
- Floris Bosch
-
Leiden, Netherlands
- Recruiting
- Leids Universitair Merisch Centrum
-
Contact:
- Erik Klok, Dr.
-
-
-
-
-
Cadiz, Spain
- Recruiting
- Hospital Universitario Puerto Real
-
Contact:
- Juan Bosco López-Saez
-
Elche, Spain
- Recruiting
- Hospital General Universitario de Elche
-
Contact:
- Francisco J. Pelegrín Mateo
-
Madrid, Spain
- Recruiting
- Clínica Universidad Navarra en Madrid
-
Contact:
- Pedro Ruiz-Artacho
-
Pamplona, Spain
- Recruiting
- Clinica Universidad de Navarra
-
Contact:
- Sofia Huerga Domínguez
-
Sevilla, Spain
- Recruiting
- Hospital Universitario Virgen del Rocio
-
Contact:
- Luis Jara-Palomares
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Documented active cancer (i.e. diagnosis of cancer within the past 6 months; recurrent, regionally advanced, or metastatic disease; currently receiving treatment or received treatment within the past 6 months)
- Objectively confirmed symptomatic or incidental recurrent VTE while on anticoagulant therapy. The previous VTE and index recurrent VTE will include symptomatic or incidentally detected proximal deep vein thrombosis (DVT) of the lower extremities; symptomatic proximal upper extremity DVT (either related to a catheter or not); symptomatic distal DVT; symptomatic or incidentally detected multiple subsegmental, segmental or more proximal pulmonary embolism (PE).
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Use of thrombolysis
- Anticoagulant treatment for the recurrent VTE for longer than 72 hours
- Treatment with fondaparinux, unfractionated heparin, prophylactic doses of LMWH, or VKAs at time of recurrent VTE
- Acute hepatitis, chronic active hepatitis, or severe hepatic dysfunction (Child Pugh C or <MELD > 10)
- Active bleeding
- Recent major surgery (<2 weeks or longer, if still at high risk for bleeding)
- Uncontrolled hypertension (systolic arterial pressure >160 mmHg)
- Known bleeding diathesis
- Platelet count <50.000 mm3
- Creatinine clearance <30 mL/min (Cockcroft-Gault formula)
- Life expectancy of less than 1 month
- Dual antiplatelet therapy or aspirin at doses ≥165 mg daily
- Current diagnosis or history of heparin-induced thrombocytopenia
- Any condition, which in the opinion of the investigator, would put the subject at an unacceptable risk from participating in the study.
- Suspected non-compliance at the time of recurrent VTE
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrent venous thromboembolism
Time Frame: 90 days
|
objectively confirmed recurrent VTE
|
90 days
|
Major bleeding
Time Frame: 90 days
|
Major bleeding per ISTH criteria
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically relevant non-major bleeding
Time Frame: 90 days
|
CRNMB per ISTH criteria
|
90 days
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- W19_237
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrence
-
Portuguese Oncology Institute, CoimbraCompletedColorectal Cancer | Recurrence, Local NeoplasmPortugal
-
Paracelsus Medical UniversityHeinrich-Heine University, Duesseldorf; Poznan University of Medical Sciences; University Hospital of Ferrara and other collaboratorsCompletedToxicity | Local Neoplasm RecurrenceAustria
-
Chinese PLA General HospitalRecruitingHCC | Recurrence TumorChina
-
The University of Hong KongHealth and Medical Research FundNot yet recruitingCancer | Fear of Cancer Recurrence
-
German Centre for Assessment and Evaluation of...Not yet recruitingComplication | Continence | Potency | Biochemical RecurrenceGermany
-
General Hospital GroeningeUniversitaire Ziekenhuizen KU Leuven; Jessa Hospital; University Hospital, Ghent and other collaboratorsNot yet recruiting
-
Dallas VA Medical CenterTerminatedSolid Tumors | Cancer RecurrenceUnited States
-
PhytoHealth CorporationCompletedNeoplasm Metastasis | Neoplasm RecurrenceTaiwan
-
The University of Hong KongHealth and Medical Research FundRecruitingCancer | Fear of Cancer Recurrence | PsychooncologyHong Kong
-
The University of Hong KongNot yet recruitingCancer | Fear of Cancer Recurrence